The Fort Worth Press - NHS to test blood screening designed to detect 13 cancers earlier

USD -
AED 3.673015
AFN 64.999782
ALL 80.947117
AMD 360.430183
ANG 1.789785
AOA 917.999777
ARS 1545.671903
AUD 1.456655
AWG 1.8
AZN 1.709472
BAM 1.743549
BBD 2.014201
BDT 124.684633
BGN 1.747831
BHD 0.37715
BIF 3010
BMD 1
BND 1.278494
BOB 11.860357
BRL 5.586302
BSD 1.00008
BTN 93.98513
BWP 13.720001
BYN 2.994357
BYR 19600
BZD 2.011304
CAD 1.41905
CDF 2314.99969
CHF 0.825495
CLF 0.025004
CLP 984.089569
CNY 6.67035
CNH 6.67757
COP 3306.86
CRC 452.34508
CUC 1
CUP 24.001212
CVE 99.225024
CZK 21.81905
DJF 177.719972
DKK 6.69708
DOP 60.701137
DZD 136.512273
EGP 53.322032
ERN 15
ETB 162.77021
EUR 0.89587
FJD 2.26045
FKP 0.745155
GBP 0.74955
GEL 2.59012
GGP 0.745155
GHS 11.710267
GIP 0.745155
GMD 74.000022
GNF 8864.999656
GTQ 7.641802
GYD 209.550384
HKD 7.84545
HNL 26.881572
HRK 6.76901
HTG 131.085575
HUF 326.443002
IDR 18074
ILS 3.18295
IMP 0.745155
INR 93.70695
IQD 1516.057857
IRR 1906075.000314
ISK 122.389884
JEP 0.745155
JMD 158.721951
JOD 0.709026
JPY 158.793987
KES 129.925372
KGS 87.449803
KHR 4080.000134
KMF 438.999811
KPW 899.999961
KRW 1342.419436
KWD 0.31107
KYD 0.833363
KZT 446.483971
LAK 22510.073815
LBP 89553.682465
LKR 332.358631
LRD 169.999198
LSL 16.395017
LTL 2.95274
LVL 0.60489
LYD 6.410662
MAD 9.755417
MDL 17.970617
MGA 4537.674286
MKD 55.125375
MMK 2099.696522
MNT 3601.450067
MOP 8.080107
MRU 40.350223
MUR 46.919901
MVR 15.409951
MWK 1734.122597
MXN 18.627801
MYR 4.05501
MZN 63.909905
NAD 16.39487
NGN 1348.110245
NIO 36.800956
NOK 9.50823
NPR 150.377549
NZD 1.78494
OMR 0.3845
PAB 1.000071
PEN 3.408278
PGK 4.491377
PHP 63.182013
PKR 276.58297
PLN 3.93845
PYG 6173.609935
QAR 3.645457
RON 4.787198
RSD 105.350071
RUB 83.174285
RWF 1479.602753
SAR 3.760416
SBD 8.097299
SCR 14.027577
SDG 601.504372
SEK 9.87835
SGD 1.282013
SHP 0.744075
SLE 22.949759
SLL 20969.504398
SOS 571.530455
SRD 37.545949
STD 20697.981008
STN 21.841652
SVC 8.750925
SYP 13001.999685
SZL 16.399741
THB 33.629695
TJS 9.190242
TMT 3.51
TND 2.980472
TOP 2.40776
TRY 50.232898
TTD 6.782502
TWD 32.998042
TZS 2643.179814
UAH 45.486291
UGX 4080.286342
UYU 40.464463
UZS 11975.30589
VES 897.18025
VND 25600
VUV 120.001108
WST 2.780103
XAF 587.652118
XAG 0.019414
XAU 0.000248077708
XCD 2.70255
XCG 1.802321
XDR 0.707052
XOF 587.652118
XPF 106.319815
YER 236.496392
ZAR 16.535402
ZMK 9001.199932
ZMW 20.375579
ZWL 321.999592
SSP 5745.814556
MXV 2.093559
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

NHS to test blood screening designed to detect 13 cancers earlier
NHS to test blood screening designed to detect 13 cancers earlier

NHS to test blood screening designed to detect 13 cancers earlier

More than 20,000 NHS patients across England are to be offered pioneering blood tests that could help doctors identify 13 different types of cancer at an earlier stage, potentially improving patients’ chances of successful treatment. The £8.

Text size:

More than 20,000 NHS patients across England are to be offered pioneering blood tests that could help doctors identify 13 different types of cancer at an earlier stage, potentially improving patients’ chances of successful treatment. The £8.5million Government-funded trial will take place at around 200 GP surgeries and will investigate whether a simple blood sample can help detect cancers that are often difficult to diagnose. Researchers hope the technology could make a significant difference for patients experiencing symptoms such as persistent bloating, abdominal discomfort or unexplained pain, which can sometimes be mistaken for less serious conditions.

The study, called STRIDE-RCT, is being led by the University of Birmingham and will involve patients aged 45 and over who attend their GP with symptoms that may indicate cancer. The tests will look for signs of 13 different cancers, including bowel, pancreatic, ovarian, stomach, liver, kidney, bladder and prostate cancer.

Other cancers being investigated include those affecting the small bowel, oesophagus, bile ducts, gallbladder and lining of the womb. Three different blood-testing technologies will be evaluated to establish how accurately they identify possible cancer and whether they can help GPs decide which patients need urgent further investigations.

Some of the tests detect tiny fragments of DNA released into the bloodstream by tumours, while others examine proteins associated with cancer. Artificial intelligence may also be used to help analyse the results. Most participants will only need to provide one or two tubes of blood during a routine GP appointment, alongside any other tests recommended by their doctor.

The research is particularly important because several cancers affecting the abdomen can develop without obvious symptoms until the disease has reached a more advanced stage. Approximately 71,000 people in England are diagnosed with pancreatic, stomach, liver, ovarian or bowel cancer each year, with almost 35,000 deaths annually from these diseases.

Early diagnosis can dramatically improve survival prospects. Around nine in ten people diagnosed with bowel cancer at stage one survive for at least five years, compared with approximately one in ten diagnosed at stage four. However, scientists have emphasised that the new blood tests will not provide a definitive cancer diagnosis.

A positive result would require further investigation, while a negative result would not necessarily rule out cancer. The trial will also examine whether the technology could help reduce unnecessary hospital referrals while ensuring patients with potentially serious conditions receive investigations promptly.

NHS England’s national clinical director for cancer, Professor Peter Johnson, has highlighted the difficulties doctors face in identifying abdominal cancers because their symptoms can resemble those of much less serious illnesses. The research follows an earlier NHS trial involving more than 142,000 volunteers who underwent testing using a different multi-cancer blood test called Galleri.

Although that study produced some encouraging findings, it did not achieve its main objective of reducing the overall number of cancers diagnosed at stages three and four. Researchers will now assess whether testing patients who already have symptoms can provide more useful information for doctors.

The University of Birmingham study is scheduled to continue until October 2031, with its findings helping to determine whether the technology could eventually become more widely available across the NHS. It has not yet been confirmed which GP practices in Worcestershire, Warwickshire or the wider West Midlands will participate.

Patients concerned about persistent or unexplained symptoms are advised to contact their GP rather than wait for the new tests to become available.

K.Ibarra--TFWP